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Biologic drugs, especially anti-TNF, are considered as the gold standard therapy in
rheumatoid arthritis. However, non-uniform efficacy, incidence of infections, and high
costs are major concerns. Novel tissue-specific agents may overcome the current
limitations of systemic administration, providing improved potency, and safety. We
developed a bispecific antibody (BsAb), combining human arthritic joint targeting,
via the synovial-specific single-chain variable fragment (scFv)-A7 antibody, and TNFα
neutralization, via the scFv-anti-TNFα of adalimumab, with the binding/blocking capacity
comparable to adalimumab -immunoglobulin G (IgG). Tissue-targeting capacity of the
BsAb was confirmed on the human arthritic synovium in vitro and in a synovium xenograft
Severe combined immune deficient (SCID) mouse model. Peak graft accumulation
occurred at 48 h after injection with sustained levels over adalimumab-IgG for 7 days
and increased therapeutic effect, efficiently decreasing tissue cellularity, and markers
of inflammation with higher potency compared to the standard treatment. This study
provides the first description of a BsAb capable of drug delivery, specifically to the disease
tissue, and a strong evidence of improved therapeutic effect on the human arthritic
synovium, with applications to other existing biologics.
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INTRODUCTION
The development of biologic agents for cancer and autoimmune disorders has revolutionized the
standard therapeutic approach. Despite the undisputed success of several biologics currently in
clinical use, some aspects are still a major source of concern. Systemic distribution and off-site
on-target effects are still unsolved issues which can lead to the lack of potency and severe
side effects in a subset of patients, constituting some of the principal drawbacks associated
with this powerful class of therapeutics (1). Although the industry is in constant search for
novel therapeutic targets to improve potency and overcome these limitations, an alternative
approach could rely on improved tissue-specific delivery. Tailored drug delivery approaches could
substantially reduce risks associated with the systemic exposure, improving safety and potency
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of new or established biological drugs. Rheumatoid arthritis
(RA) represents an example of a severe chronic inflammatory
condition localized mainly to an organ system (the joint) where
tissue-specific therapeutic targeting could provide benefits to
the patients.
Rheumatoid arthritis represents the most common and severe
form of inflammatory arthritis with significant association with
morbidity and mortality (2, 3). It affects ∼1% of the adult
population in Western Europe with an average age of onset
of 40 years and an increase in incidence with rising age (4).
The pathogenic processes in RA involve disequilibrium in the
cytokine network in favor of pro-inflammatory stimuli, with
elevated expression of key cytokines such as tumor necrosis factor
(TNF), interleukin (IL)-1β, and IL-6 (5).
Strategies for RA therapy involve the use of non-steroidal anti-
inflammatory drugs (NSAID) and synthetic disease-modifying
antirheumatic drugs (sDMARD) as first-line treatments. Recent
advances in the development of biologic DMARD (bDMARD)
have opened the gates to the anti-cytokine era, leading to the
rise of the anti-TNF biologics, currently considered the gold
standard care for RA (6). However, a sizeable proportion of
patients (30–40%) do not respond adequately, and treatment-
free remission is still rarely achieved (6–8). It is plausible
that different rates and efficiencies of tissue penetrance and
accumulation, associated with suboptimal cytokine blockade
at the site of interest, could explain anti-cytokine treatment
resistance. Increasing drug concentrations in the disease tissues
through amore tailored tissue-specific approach has the potential
to improve the therapeutic range without increasing the systemic
dose and the associated risk of toxicity.
Bispecific antibodies (BsAbs) are gaining momentum with
increasing clinical success, as an emerging class of biological
therapeutics characterized by simultaneous binding capacity
to two distinct epitopes. This has been successfully applied
in cancer therapy, with bispecific constructs being able to
interact with CD3 and cancer-specific antigens to activate
effector cells in the proximity of the disease tissues (9). Here,
we describe a bispecific construct for the treatment of RA
by combining a well-established anti-TNF therapeutic domain
[single-chain variable fragment (scFv)-adalimumab, HumiraTM,
AbbVie Inc. North Chicago, IL, USA] with a tissue-targeting
domain we previously described (scFv-A7) (10). The scFv-
A7 showed remarkable tissue and disease specificity for the
microvascular compartment of the human arthritic synovium,
with no detectable reactivity with a vast array of human tissues,
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antirheumatic drug; bDMARD, biologic disease modifying antirheumatic drug;
scFv, single-chain variable fragment; His, histidine; EC50, effective concentration
50%; IC50, inhibitory concentration 50%; KD, kinetic constant; Ka, association
kinetic; Kd, dissociation kinetic; MMP, matrix metallo-proteinase; TIMP, tissue-
inhibitor of metallo-proteinase; M-CSF, macrophage colony-stimulating factor;
GM-CSF, granulocyte-macrophage colony stimulating factor; CIA, collagen
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including normal human synovium and other inflammatory
diseases (10). ScFv-A7 antibody displays all properties of an
ideal candidate for targeted therapy in RA, with expectations
of increasing therapeutically relevant concentrations within the
disease tissue while reducing systemic distribution. The results
reported here represent the first preclinical evidence of tissue-
specific delivery and therapeutic efficacy within the disease tissues
using a commonly prescribed bDMARD that may pave the way
to translating this approach into patients.
MATERIALS AND METHODS
Antibody Cloning Strategy
ScFv-A7 VH/VL sequences were obtained from the phage display
clone (10). E2 (anti-dipeptidyl aminopeptidase-like protein 6)
scFv-Fc sequence was kindly provided by Professor D. Sblattero.
adalimumab sequence was obtained from the patent (11). All
adalimumab were cloned in fusion with the IgG1 Fc CH2–CH3
region, and bispecific constructs in pDuo vectors, including the
Y407T (for adalimumab) or the T366Y mutation (for A7 and E2)
(12, 13).
Antibody Expression and Characterization
Antibodies were expressed by stably transfected Chinese hamster
ovary (CHO)-S cell line and purified using Talon R© Metal
Affinity Resins (Clontech Laboratories, Inc., Mountain View,
CA, USA), for BsAb A7/adalimumab and E2/adalimumab, or
protein A Sepharose CL-48 resin (GE Healthcare, Chicago, IL,
USA) for A7 scFv-Fc and adalimumab scFv-Fc. Antibodies were
biotinylated using an EZ-Link Sulfo-NHS-SS Biotinylation Kit
(ThermoFisher Scientific Inc., Waltham, MA, USA) according
to the manufacturer’s protocol. Antibody purity was determined
by SDS-PAGE via SYPRO Ruby Protein Gel Stain (Life
Technologies, Carlsbad, CA, United States).
Human Tissues
Synovia from patients with RA were obtained during joint
replacement surgery, and skin tissues were obtained from
patients undergoing plastic surgery. All patients had given
informed consent as approved by the institutional ethics
committee (REC 05/Q0703/198). Samples were frozen using
CryoStor R© (Sigme-Aldrich, St. Louis, Mo, USA) freeze media
according to themanufacturer’s instructions and stored at−80◦C
until usage.
Animals
Our own colony of the SCID mice (SCID beige mouse,
CB17.Cg-PrkdcSCIDLystbg−J/Crl mice) were housed at Charles
River Laboratories and handled at Queen Mary University of
London during the experimental procedure in accordance with
the institutional guidelines and procedures approved by the
UK Home (Scientific Procedures Act 1986, Project License
PPL 7008259).
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Determination of Anti-TNF Activity
Anti-TNF ELISA, cytotoxicity assay, and surface plasmon
resonance (SPR) analysis were performed as previously
described (14).
Histology
Analysis of tissue morphology on frozen tissue sections was
performed upon acetone fixation by H&E staining on six
sections per sample spanning 120µm. Immunohistochemistry
on frozen tissue sections were stained with mouse anti-
human CD3, CD20, CD68, CD90 or von Willebrand factor
(vWF), and CD31 (Dako, Hamburg, Germany), according
to the manufacturer’s recommendations, and detected with
EnVisionTM horseradish peroxidase (HRP; Dako) and a 3,3′-
diaminobenzidine (DAB; Dako) substrate solution. Staining
was performed on four sections per sample spanning 120µm.
Immunofluorescence on frozen tissues were stained with
20µg/ml of biotinylated test antibody and mouse anti-human
vWF (Dako) at 1µg/ml. Biotinylated antibodies were detected
with streptavidin-conjugated Alexa Fluor 488 (Life Technology),
and anti-vWF was detected with a goat anti-mouse IgG
Alexa Fluor 555 (Life Technology). Immunohistochemistry on
formalin-fixed paraffin-embedded tissue sections were dewaxed,
and the antigen was retrieved following proteinase K digestion
(Dako). Sections were incubated with 20µg/ml of biotinylated
antibody and detected with streptavidin-HRP, followed by DAB
incubation. Quantification of tissue cellularity from H&E and
immunohistochemistry was performed using cellSens Dimension
(Olympus, Tokyo, Japan) via automated cell count using adaptive
thresholding. Cellular density was expressed as % of the tissue
area covered by pixels above threshold.
Synovium Xenograft SCID Mouse Model
Rheumatoid arthritis synovium and skin tissues were thawed
from liquid nitrogen immediately before surgery, washed, and
then kept in RPMI 1640 medium. Beige male and female
SCID mice (6–8 weeks old) were housed in groups of six per
cage. The mice were anesthetized, and biopsies were inserted
subcutaneously in the dorsal skin (two synovium biopsies over
the scapulae, two skin biopsies over the kidney region), as
previously described (15). To avoid the cage effect, mice were
randomized into treatment groups within a cage immediately
before the first injection. Mice were injected intravenously with
3 mg/kg of test antibodies at day 7 and 14 post-transplant. The
sample size was calculated according to the previous studies
(16, 17). The operator performing the experiment was blind
for the treatment. Animals were culled 21 days post-transplant,
tissues were harvested for RNA extraction and histology, and
blood were collected for cytokine measurements (some of the
grafts have been excluded due to the limited amount of tissue).
Six mice per group were used for a total of 12 synovium and 12
skin grafts.
In vivo Imaging
In vivo fluorescence images at various time points after
intravenous (IV) injection of 3 mg/kg Cy5.5 labeled Ab
(6, 24, 48, 72, 144, and 168 h) were acquired and analyzed
with a Lumina IITM IVIS (In Vivo Imaging System)
instrument (Caliper Life Sciences, Waltham, MA, USA)
with quantification of bioluminescence performed using
Living ImageTM software (Caliper Life Sciences) according
to the manufacturer’s instructions. Mice were maintained
under isoflurane inhalation anesthesia. Control animals were
injected with Phosphate-buffered saline (PBS). The signal
emitted by grafts Region of interest (ROI) was measured,
and data expressed as radiant efficiency and quantified as
photons s−1 cm−2 sr−1.
RNA Expression
The RNA from grafts was extracted using TRIZOL as previously
described (16) and quality checked at the NanoDrop 2000C
(Labtech, Heathfield, UK). A maximum of 500 ng total RNA was
reverse transcribed and the generated cDNA stored at −20◦C
until use.
Gene expression profiling was performed by quantitative
real-time PCR using 15 ng/well of cDNA in an ABI Prism
7900HT Fast Real-Time PCR System (Applied Biosystems, Foster
City, CA, USA). Relative expression was calculated using the
comparative threshold cycle (Ct) method; Ct cycle of the human
endogenous control glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used to normalize for the initial cDNA amount.
Samples with Ct value of GAPDH ≥ 26 were excluded from
the analysis.
Cytokine Analysis in SCID Mice Sera
Mice sera were collected through terminal bleeding at day
14. Quantification of human cytokines concentrations was
performed using human-specific V-Plex immunoassay (Meso
Scale Discovery, Rockville, MA, USA) and analyzed using a
QuickPlex SQ 120 instrument (Meso Scale Discovery) according
to the manufacturer’s recommendations.
Statistical Analysis
All data sets were first screened with the ROUT test to identify
statistically significant outliers (18). Statistical comparison within
treatment groups was performed using the Mann–Whitney
unpaired non-parametric test in GraphPad Prism v6 (GraphPad
Software Inc., San Diego, CA, USA).
RESULTS
Bispecific Antibody Design
To obtain maximum therapeutic potency, the anti-TNF antibody
adalimumab was selected as the effector moiety. The parent
adalimumab IgG antibody was first converted in the scFv format,
supported by the scFv origins of adalimumab (19), maintaining
binding specificity and pharmacokinetics as previously reported
(20, 21). As tissue targeting partner, the scFv-A7 was selected
for its arthritic synovium specificity (10). All antibodies were
demonstrated to be in the expected format when expressed as
scFv-Fc fusion constructs (Figure 1).
To create a BsAb, we adopted the “knob-into-hole” technology
based on the replacement of a small amino acid with a larger
one (T366Y) in the IgG CH3 domain of one chain and an
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FIGURE 1 | Characterization of scFv-Fc antibody constructs. (A) ScFv of interest was cloned in fusion with the immunoglobulin (IgG) Fc region as single-chain variable
fragment (scFv)-Fc construct. Bispecific scFv-Fc antibody carried the A7 scFv-Fc fused to the Fc chain containing the “hole” T366Y mutation while the adalimumab
(Continued)
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FIGURE 1 | scFv-Fc chain contained the “knob” Y407T substitution. (B) Bispecific antibody expression vector contained the adalimumab scFv sequence fused to the
CH2-CH3 (Y407T) Fc domain and the SV5 tag while the A7 scFv was fused to the CH2-CH3 (T366Y) Fc region and to a 6-His tag. The two chains were linked in a
monocistronic sequence via the FMDV 2A peptide to allow an equal expression of the two chains from a single RNA. (C) SDS-PAGE analysis of the scFv-Fc and
bispecific scFv-Fc antibodies shows the presence of a single band around 60 kDa compared to the heavy (50 kDa) and light (25 kDa) chains visible for the parent
adalimumab IgG antibody. (D) Tumor necrosis factor (TNF) binding capacity of bispecific antibodies and reference adalimumab IgG and scFv-Fc antibodies as
determined via ELISA. Both bispecific antibodies and adalimumab scFv-Fc format showed comparable TNF binding capacity to the parent adalimumab IgG. No
binding could be detected with the A7 scFv-Fc antibody. (E) Neutralization of TNF in a TNF induced cytotoxicity assay using L-929 cell line was efficiently obtained
with the bispecific antibodies as expressed by the 50% inhibitory concentration (IC50). Potencies similar to adalimumab IgG and adalimumab scFv-Fc were
determined for both bispecific antibody constructs. No rescue of cellular viability was obtained with the A7 scFv-Fc antibody. Values expressed as mean ± SEM.
(F) Surface plasmon resonance sensorgrams representing binding kinetics of adalimumab scFv-Fc and A7/adalimumab to TNF. TNF concentrations were 20 nM (light
blue), 8 nM (purple), 3.2 nM (blue), 1.28 nM (green), and 0.512 nM (red). Kinetic comparison between adalimumab scFv-Fc, A7-adalimumab, and A7 scFv-Fc is
expressed with the sensorgram of interaction with TNF at 20 nM. (G) Surface plasmon resonance kinetic measurements of anti-TNF antibodies. ka, association rate
constant; kd, dissociation rate constant; KD, affinity constant. Adalimumab IgG kinetic measurements were previously reported in the literature (14).
opposite substitution in the second chain (Y407T), preventing
homodimerization due to steric hindrance and protein instability
(22). To avoid issues related to heavy and light chain mispairing,
common in most of the IgG-like BsAb formats, the variable
domains were designed as scFv (Figure 1A). To ensure a correct
1:1 ratio of expression and increase heterodimerization efficiency,
the two chains were coded in the same vector linked via the
2A self-processing peptide as previously described (12), further
processed by a furin cleavable site to ensure complete removal
of the 2A peptide sequence (Figure 1B). The BsAb scFv-Fc
format for A7/adalimumab is therefore a dimer containing both
variable domains and the Fc IgG region with an approximate
molecular weight of 120 kDaadalimumab, resulting in two
bands at 60 kDa in a reduced SDS-PAGE, corresponding to
the A7 scFv-Fc and the adalimumab scFv-Fc chains, confirming
heterodimer formation (Figure 1C). All three antibodies showed
comparable stability as determined by differential scanning
fluorimetry (DSF) (Supplementary Figure 1). Additionally, a
high degree of heterodimerization of our system was confirmed
using a truncated scFv-Fc bispecific construct as described in
Supplementary Figure 2.
A non-targeting bispecific construct comprising the scFv-E2
and scFv-adalimumab (E2/adalimumab) was also generated as
the negative control.
Characterization of in vitro Targeting and
Therapeutic Function
TNF binding and neutralization were investigated using
an ELISA and a cytotoxic assay. Despite the conversion
to scFv format, the adalimumab scFv-Fc antibody showed
almost identical binding capacity for TNF when compared
to the parent adalimumab IgG antibody. A7/adalimumab
and the control of E2/adalimumab bispecific antibodies
displayed TNF binding capacity with a slight half-maximal
effective concentration (EC50) shift (Figure 1D). TNF-
induced cytotoxicity assay showed a similar neutralizing
dose–response curve between adalimumab IgG and adalimumab
scFv-Fc antibodies, while no rescue of cellular viability was
detected with A7 scFv-Fc. Comparable TNF inhibition was also
determined for the bispecific antibodies with a half-maximal
inhibitory concentration (IC50) characterized by a 2-fold
increase compared to adalimumab scFv-Fc (Figure 1E). This
increase in EC50 and IC50 is most likely due to the presence
of only one anti-TNF domain and consequently a halved TNF
binding/blocking potential.
TNF binding kinetics and association (ka) and dissociation
(kd) rates were further characterized via SPR (Figures 1F,G).
The previously published data on adalimumab IgG (14) shows
comparable kinetics to the scFv-Fc format and to the bispecific
A7/adalimumab antibody with an affinity (KD) of 49, 23,
and 33 pM, respectively, further demonstrating unaltered TNF
interaction profiles for the newly developed antibody formats.
No TNF binding was detected with the A7 scFv-Fc antibody.
Interestingly, while the kinetics remained unchanged, the
maximal response of the A7/adalimumab BsAb at saturating
concentrations of TNF (20 nM) was only half of what was
detected for adalimumab scFv-Fc (Figure 1F). These data
confirm that the monovalent TNF binding of the bispecific
format does not affect the kinetics of interaction with soluble
TNF but only results in a reduced number of interactions.
It is also apparent that one paratope on a single arm can
efficiently target and block the TNF trimer, further supporting
the development of bispecific antibodies with only one anti-
TNF domain.
We then tested the capacity of the BsAb A7/adalimumab
to retain tissue targeting capacity using immunohistochemistry
(Figure 2A) and immunofluorescence (Figure 2B) in the human
arthritic synovium (n = 3) as previously described for scFv-
A7 (10). Strong reactivity was detected with the perivascular
compartment of the synovial microvasculature with a similar
pattern to the reference A7 scFv-Fc antibody. No staining
could be detected with the E2/adalimumab BsAb, confirming its
suitability as a non-targeting control antibody.
In vivo Localization of A7/Adalimumab
BsAb in the Human Synovium-SCID Mouse
Xenograft Model
The tissue localization properties of the BsAb A7/adalimumab
to the human arthritic synovium were addressed by using a
Cy5.5 conjugated construct injected intravenously into SCID
mice double grafted with the human arthritic synovium (n = 4)
and control human skin (n= 4). The use of this xenograft mouse
model of arthritis provides a unique opportunity to evaluate
therapeutic accumulation in human tissues. Further, the presence
of the normal human skin graft serves as an internal control for
non-targeted tissue accumulation.
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FIGURE 2 | Reactivity in the human arthritic synovium. (A) Immunohistochemistry on human arthritic synovium stained with biotinylated A7 scFv-Fc, adalimumab
scFv-Fc, A7/adalimumab and E2/adalimumab at 20µg/ml (n = 3). Binding of antibody to tissue section detected with horseradish peroxidase (HRP) conjugated
avidin–biotin complex. Red arrows indicate A7 staining. Blue arrows indicate anti-TNF staining. Insert represents magnification of vasculature and reactive cells.
(B) Immunofluorescent staining on arthritic synovium with biotinylated A7 scFv-Fc, adalimumab scFv-Fc, bispecific A7/adalimumab, and bispecific E2/adalimumab at
20µg/ml in combination with anti-von Willebrand factor (vWF). Biotinylated antibody detected with streptavidin-Alexa Fluor 488 (green). Anti-vWF detected with
anti-mouse Alexa Fluor 555 (red). DAPI counterstain to depict nuclei (blue). Scale bar in representative pictures 100µm.
Antibody localization in the grafts was assessed via fluorescent
imaging starting at 6 h post-injection and 24 h increments until
day 7. In vivo fluorescent imaging showed a preferential synovial
accumulation for adalimumab scFv-Fc and A7/adalimumab
BsAb starting at 24 h with a signal detectable up to 7 days
post-injection (Figure 3A). Analysis of the average radiant
efficiency in the graft region revealed that the peak of
accumulation of A7/adalimumab in the synovial graft occurred
at 48 h with significantly prolonged retention in the target
tissue compared to adalimumab scFv-Fc for up to 7 days
(p < 0.05) (Figure 3B). Further, in the human skin graft used
as negative control, both antibodies demonstrated similar basal
levels of fluorescence (Figure 3B). Comparison of the average
radiance efficiency between synovium grafts and skin grafts
revealed a significantly higher synovial tissue accumulation
for the BsAb A7/adalimumab between 48 h and 7 days post-
injection (p < 0.05) while adalimumab scFv-Fc, although not
statistically significant, exhibited a higher fluorescence intensity
in the synovial grafts only at 48 h (p = 0.1) that quickly
resolved to the levels measured for the skin grafts at 72 h post-
injection (Figure 3B, Supplementary Figure 3). Further, human
IgG serum levels 1 week after injections were significantly higher
in the A7/adalimumab treatment group, indicating an increased
half-life (Supplementary Figure 4).
Therapeutic Efficacy of A7/Adalimumab in
the Human Synovium-SCID Mouse
Xenograft Model
In order to establish that BsAb A7/adalimumab maintained
therapeutic efficacy in vivo, we adopted the human synovium-
SCID mouse xenograft model. The mice were treated 1 week
after grafting with IV injections at day 0 and 7 of 3 mg/kg
adalimumab scFv-Fc, A7/adalimumab, E2/adalimumab (non-
targeting antibody), or A7 scFv-Fc and PBS (control group).
Six animals per group were receiving two human skin and two
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FIGURE 3 | In vivo localization in human synovium xenograft SCID mouse model. (A) SCID mice double grafted with the human arthritic synovium (top) (n = 4) and
human normal skin (bottom) (n = 4) were injected intravenously with Cy5.5 conjugated antibody and imaged at 6, 24, 48, 72, 144, and 168 h. As control, PBS was
injected. Blue circles indicate graft location in fluorescence images. (B) Quantification of average radiant efficiency in the region of interest encompassing the graft
location shows an increased intensity that correlates with the amount of Cy5.5 conjugated antibody accumulated in the tissue. Values were expressed as mean ±
SEM. Mann–Whitney non-parametric test (*p < 0.05).
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arthritic synovium grafts (n = 12). Grafts were harvested at day
14 and divided for immunohistochemical analysis to measure
cellularity levels and mRNA extraction for molecular profiling.
Tissues with satisfactory human GAPHD mRNA expression
levels (≤26 PCR amplification cycles) were considered viable and
retained for further analysis.
As shown in Figure 4Aa, varying degree of cellularity could
be detected between the four treatment groups with consistently
lower levels in the A7/adalimumab treatedmice. A slight decrease
in total cell content could also be detected in the adalimumab
scFv-Fc group. The stained sections were analyzed via the
imaging software to quantify the number of cells present per
tissue section, revealing a significant reduction in the total cell
content in the A7/adalimumab BsAb treatment compared to
control, adalimumab scFv-Fc and E2/adalimumab (p < 0.01,
p < 0.05, and p < 0.001, respectively) (Figure 4Ba). As the
degree of tissue vascularization can affect graft survival and cell
viability, tissue sections were stained for human vWF and CD31
to highlight the vasculature (Figure 4Ab). A similar vascular
density was determined across all treatment groups and between
synovium and skin grafts (Figure 4Bb).
Synovium grafts were further stained for CD3, CD68, CD20,
and CD90 to identify specific cell populations (Figure 4Ac–f,
respectively). A similar B-cell (CD20) and fibroblast (CD90)
content was present in all tissues tested (Figure 4Be,f), while
a decreasing trend for T cells (CD3) could be detected
in the adalimumab scFv-Fc (p < 0.05 and p = 0.05)
and A7/adalimumab (p = 0.1 and p = 0.05) treatment
groups compared to control and E2/adalimumab (Figure 4Bc).
Remarkably, the A7/adalimumab treatment was more effective in
decreasing the number of CD68+ cells (macrophages) with levels
significantly lower than control and E2/adalimumab groups
(p < 0.05) (Figure 4Bd).
Molecular profiling for specific markers of inflammation was
performed on synovial grafts from the four treatment groups to
identify changes in molecular signatures of treatment response.
The A7/adalimumab treatment group showed a marked decrease
in pro-inflammatory cytokine mRNA expression. Levels of
IL-8 and TNF were consistently lower than the control
group (p < 0.01 and p < 0.05, respectively), while IL-1β
and IL-6 levels showed a decreasing trend, without reaching
statistical significance (p = 0.1) (Figure 5). These data indicate
efficient TNF blockade with consequent downregulation of key
cytokines as previously described (23, 24). The pro-inflammatory
environment in RA synovium can stimulate synoviocytes
of the lining layer to produce matrix metalloproteinases
(MMP) (25–28). The expression of MMP-1,−2,−3,−9, and−13
mRNA was compared between the treatment groups. BsAb
A7/adalimumab treatment was able to significantly reduceMMP-
1 and MMP-3 mRNA expression compared to adalimumab
scFv-Fc (p < 0.05). Levels of MMP-2,−9, and−13 did not
show modulation compared to the control group, while
adalimumab scFv-Fc was able to significantly reduce MMP-
9 mRNA expression (p < 0.01) (Figure 5). Also, the levels
of tissue inhibitor of metalloproteinases (TIMP)-1 mRNA
were affected by adalimumab scFv-Fc treatment compared to
control (p < 0.05) (Figure 5). Consistent with data already
described in Figure 5, A7/adalimumab treatment resulted in a
marked decrease of granulocyte-macrophage (GM)-CSF mRNAs
compared to control (p < 0.05) (Figure 5).
To confirm the reduced expression of pro-inflammatory
markers detected in mRNA analysis, human cytokine
concentrations in SCID mice sera were determined using
a multiplex sandwich ELISA assay. Circulating levels of
granulocyte-macrophage colony stimulating factor (GM-CSF)
did not show significant changes across the treatments, while
IL-8 serum concentrations were lower in the A7/adalimumab
treatment group compared to control (p < 0.05). Interestingly,
both adalimumab scFv-Fc and A7/adalimumab showed a
marked decrease in soluble TNF levels compared to control
and E2/adalimumab groups (p < 0.01 for adalimumab scFv-Fc
and p < 0.05 for A7/adalimumab) (Figure 6). Taken together,
these results indicate an efficient anti-TNF activity of the BsAb
A7/adalimumab, resulting in a more potent anti-inflammatory
effect compared to the parent Anti-TNF antibody.
DISCUSSION
Current successful therapeutics for the treatment of RA are
based on blockade of pro-inflammatory pathways, targeting
cytokines or immune effector cells. Although clinically efficacious
due to the crucial importance of these pathways in immune
surveillance/response, their targeting can often lead to increased
risk of infections and/or reactivation of latent diseases such
as tuberculosis (6, 29, 30). Furthermore, the systemic broad
distribution of these targets may reduce the effective therapeutic
dose reaching successfully the tissue of interest. This will in turn
require an increased administration dose, with the associated
risk of toxicity, to reach the optimal therapeutic concentration
range in the disease tissue (23, 31). The development of a
therapeutic molecule containing a second moiety with the tissue
and/or disease specificity represents a powerful approach to
increase pharmaceutical potency and reduce systemic side effects.
Antibodies are exceptionally suited for this task due to their
binding specificity and versatility, embodying the “magic bullet”
concept conceived by Paul Ehrlich (32).
Several constructs are currently in development for the
treatment of rheumatoid arthritis in the preclinical or early
clinical stage as have been extensively reviewed (1). An example
of this is the development of scFv antibody fragments against
extra-domain (ED) A and B splicing variants of fibronectin that
are reexpressed during inflammation and cancer and have been
successfully conjugated with effector molecules (33–36). Our
group and collaborators demonstrated the successful delivery
of IL-4 in vivo using a synovium targeting peptide in the
xenograft SCID mouse model, and the selective accumulation
of an anti-C5 antibody fused to the same synovium targeting
peptide in affected joints of rodent models of arthritis (37,
38). Similarly, the synovium targeting peptide conjugated with
methotrexate-loaded nanoparticles increased the accumulation
of these nanostructures in inflamed joints (animal models of
arthritis) compared to naked nanoparticles and showed higher
efficacy in comparison with conventional doses of methotrexate
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FIGURE 4 | Histomorphological features of human synovium xenografts. (A) Immunohistochemical analysis of synovial tissues from xenograft mice receiving PBS or
A7 scFv-Fc (control group), adalimumab scFv-Fc, A7/adalimumab, or E2/adalimumab. H&E staining reveals the total cell population within the tissues, displaying a
(Continued)
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FIGURE 4 | reduced cellularity in the A7/adalimumab group (a). Staining for specific cell types was performed with antibodies targeting vWF/CD31 (endothelial cells)
(b), CD3 (T-cells) (c), CD68 (macrophages) (d), CD20 (B-cells) (e), and CD90 (fibroblasts) (f). Brown staining indicates the presence of antibody binding. The staining
shows a reduced CD68 content in the A7/adalimumab and adalimumab scFv-Fc groups compared to control or non-targeting antibody E2/adalimumab. Similar
vascular content, CD3+, CD20+, and CD90+ cells were present in all tissues. (B) Stainings of graft tissue sections were analyzed with cellSens P imaging software
tool using adaptive thresholding to quantify the area fraction of the stainings. H&E stainings were analyzed for hematoxylin stained nuclei content (a). vWF-CD31
staining was analyzed to quantify total vascular density across the treatment groups and synovium/skin grafts (red square to indicate values measured on skin
xenografts) (b). CD68 (d), CD3 (c), CD20 (e), and CD90 (f) analyses revealed the cell area fraction for macrophages, T cells, B cells, and fibroblast, respectively. Control
n = 16; adalimumab scFv-Fc n = 8; A7/adalimumab n = 9; E2/adalimumab n = 7. Values were expressed as mean ± SEM. Mann–Whitney non-parametric test
(***p < 0.001, **p < 0.01, *p < 0.05).
FIGURE 5 | mRNA expression profiling in human synovium xenografts. mRNA expression in synovium grafts from mice receiving PBS and A7 scFv-Fc (control),
adalimumab scFv-Fc, A7/adalimumab, or E2/adalimumab were represented as relative expression compared to the median of the control group. Grafts were
harvested 7 days after second injection. Control n = 16; adalimumab scFv-Fc n = 8; A7/adalimumab n = 9; E2/adalimumab n = 7. Values were expressed as mean
± SEM. Mann–Whitney non-parametric test (*p < 0.05, **p < 0.01).
(39), further confirming the validity of targeted therapy in an
arthritic context.
The scFv antibody adopted in this study (scFv-A7) proved
to specifically target the microvascular compartment of the
human arthritic synovium with no detectable reactivity with
other human tissues, both in healthy and disease conditions
(10). This elevates it as a unique tool for the treatment of
the human arthritic condition, with increased disease tissue
specificity, and consequently improved safety, compared
to more widespread moieties such as the anti-extradomain
A of fibronectin (anti-EDA) or similar inflammation
targeting domains.
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FIGURE 6 | Human cytokine concentrations in mouse sera. Selected human cytokine concentrations in sera collected at day 14 from mice receiving PBS and A7
scFv-Fc (control) (n = 12), adalimumab scFv-Fc, A7/adalimumab, or E2/adalimumab (n = 6) were measured using multiplex sandwich immunoassay. Values were
expressed as mean ± SEM. Mann–Whitney non-parametric test (**p < 0.01, *p < 0.05).
Ligand-based vascular targeting of disease tissue is an
attractive strategy for the treatment of conditions characterized
by extensive neo-angiogenesis and vascular remodeling. This
approach is likely to improve the therapeutic index of available
therapeutic agents, increasing safety by targeting disease-specific
antigens in the vascular compartment and selectively delivering
drug in vivo, sparing healthy organs. These features underpinned
our strategy of combining the gold standard for anti-TNF
therapy adalimumab (6) with scFv-A7 for functional tissue-
specific delivery in a BsAb format, providing proof of concept in
RA. The use of an scFv-Fc fusion structure is known to prevent
heavy and light chain mispairing and contribute to increasing
heterodimerization efficiency. In addition, this format has been
shown to maintain long serum half-life and secondary Fc effector
functions, such as antibody-dependent cellular cytotoxicity and
complement-dependent cytotoxicity (12, 22). Adalimumab was
shown to maintain binding and neutralizing capacity as an scFv
compared to the IgG format (19, 21), which was preserved in the
BsAb design described here. The scFv-Fc format of adalimumab
showed TNF binding capacity with similar kinetic properties
compared to the original antibody (14). In addition, the scFv-Fc
antibody was biologically active, rescuing L-929 cells from TNF-
induced cytotoxicity with an IC50 value closely comparable to
the parent antibody. Despite adalimumab having been shown to
form complex multimeric structures with soluble TNF, with the
most stable binding configuration consisting of three separate
TNF homotrimers and three adalimumab antibodies (40), the
monovalent nature of the A7/adalimumab BsAb construct was
still able to bind TNF with comparable kinetics and to efficiently
block TNF biological activity.
Importantly, the BsAb A7/adalimumab proved to be more
effective than the adalimumab scFv-Fc antibody in localizing the
target tissue in vivo, maintaining significantly higher levels over
the course of 7 days with a single injection. Due to the presence of
higher TNF content in the synovial graft compared to the control
human skin graft, it is plausible to speculate that the initial
accumulation of adalimumab scFv-Fc at 48 h may be driven
by the presence of TNF in the target tissue. However, a rapid
decrease to the levels observed in the skin graft was determined
only for adalimumab scFv-Fc, while the BsAb A7/adalimumab
retained levels above both skin graft and parent antibody for
the duration of the treatment. Analysis of synovium and skin
grafts revealed a comparable vascular density, ruling out the effect
of degree of vascularization as the driving force for synovial
accumulation. Further, the previous data on this model have
shown that an injected non-targeting isotype control antibody
would still show synovial grafts uptake, reminiscent of our
adalimumab scFv-Fc (17). As all the constructs described here
are characterized by a similar structure and molecular weight,
passive tissue diffusion and serum half-life in SCID mice are
expected to be comparable. This suggests that the A7-targeting
domain is responsible for faster tissue localization and sustained
intra-graft concentration over what can be expected solely by
passive distribution.
Therapeutic efficacy was evaluated using the human
synovium xenograft SCID mouse model, as opposed to the
classic collagen-induced arthritis (CIA) model. Although the
xenograft model does not allow the evaluation of cartilage and
bone erosions associated with RA, it does offer the unparalleled
advantage of directly testing the effect of human-specific
biologic agents, such as the anti-TNF adalimumab, on cellular
infiltration and cytokine production in its natural human
microenvironment, accelerating translation to the human
disease. The previous studies have shown the formation
of functional anastomoses between murine and human
vasculature within the grafts, allowing the preservation of
a fully functional human microvascular compartment. This
included the expression of disease-specific vascular addressins,
pro-inflammatory cytokines, and the preservation of functional
lymphoid aggregates with local B-cell differentiation and anti-
cyclic citrullinated peptide (anti-CCP) antibody production
(10, 15, 41, 42).
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The previous data from our group have demonstrated that
intra-graft injections of human TNF can stimulate the expression
of cellular adhesion molecules (CAM), promoting in vivo
recruitment of peripheral blood lymphocytes (15). Similarly,
TNF blockade should reduce the expression of CAMs and other
markers associated with inflammation, resulting in a decreased
cellularity and resolution of inflammation. Early studies on
the activity of anti-TNF antibodies have demonstrated that
treatment efficacy was accompanied by a decrease in synovial
cellularity and a reduction of CD68+ cells in RA patients (43–
45). Treatment of grafted mice with IV injections of the BsAb
A7/adalimumab was more effective than adalimumab scFv-Fc
in reducing synovial cellularity with a more pronounced effect
on CD68+ cells. This was mirrored by a reduction of GM-
CSF mRNA expression. Further, treatment with A7/adalimumab
was also able to efficiently reduce mRNA expression and serum
concentrations of pro-inflammatory cytokines, such as IL-8 and
TNF, while other cytokines such as IL-1β and IL-6 showed a
downregulation, without reaching statistical significance. These
results are consistent with the previous reports in the literature,
where TNF blockade is associated with the reduction of key pro-
inflammatory cytokines, such as IL-1, IL-6, IL-8, and GM-CSF
(23, 24, 46). Elevated expression of MMPs in the synovium has
been previously described in RA (25–28) and the treatment with
anti-TNF agents has shown to downregulate MMP expression in
patients (47). Similarly, A7/adalimumab was able to significantly
decrease MMP-1 and MMP-3 mRNA expression in the grafts
with a more potent effect compared to adalimumab scFv-Fc.
Overall, the BsAb A7/adalimumab consistently showed a potent
and efficient anti-inflammatory activity within the arthritic
synovial grafts.
In summary, here we described a novel therapeutic antibody
with improved potency and tissue specificity and provided
evidence for increased pharmacological activity in the human
arthritic synovium with a strong indication for efficacy in the
human disease. By design, the BsAb developed in this study
contained only one anti-TNF binding domain. It is plausible
to assume that by maintaining an efficient anti-TNF activity
in the disease tissue with only half TNF binding potential,
compared to standard therapy, would translate in lower systemic
TNF engagement and increased safety. In practical terms, the
use of such BsAb molecules in the clinical care of chronic
arthritis may also allow for a reduced treatment regimen,
owing to the improved potency, and consequently reducing
the associated healthcare costs. Furthermore, this new BsAb
construct has the potential to represent a novel platform for
tissue-specific drug delivery in RA by combining the unique
properties of the A7 synovial targeting domain to the effector
functions of appropriate anti-rheumatic biologics. This strategy
could conceivably be extended to other existing anti-cytokine
antibodies with the intent of developing therapeutic agents with
reduced systemic exposure, improved potency, enhanced safety
profile, and reduced treatment costs.
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